Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-003304-12 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| pregabalin | Active Comparator |
| |
| placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pregabalin | Drug | capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization |
|
| Measure | Description | Time Frame |
|---|---|---|
| Baseline Mean Pain Score | This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. | Baseline |
| Change From Baseline to Week 15 in Weekly Mean Pain Score | This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. | up to Week 15 |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Global Impression of Change (PGIC) at Week 15 | A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale. | Week 15 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tennesse Valley Pain Consultants | Huntsville | Alabama | 35801 | United States | ||
| Dedicated Clinical Research |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30242745 | Derived | Markman J, Resnick M, Greenberg S, Katz N, Yang R, Scavone J, Whalen E, Gregorian G, Parsons B, Knapp L. Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. J Neurol. 2018 Dec;265(12):2815-2824. doi: 10.1007/s00415-018-9063-9. Epub 2018 Sep 21. |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Participants had clinic visits at screening, randomization, and during the treatment period, and a phone contact for follow-up after the last taper dose. All the eligible participants were randomly assigned (1:1) to 15 weeks of treatment with Pregabalin or Placebo.
A total of 187 centers participated in the study in 14 countries.
During screening, with the exception of daily pain score data that was collected to determine participants eligibility, no participants were treated with active drug and no efficacy data were collected. Only safety and no efficacy data was collected during the taper period.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Pregabalin | Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase. |
| FG001 | Placebo |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo | Drug | capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization |
|
| Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS) |
This is an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" [unable to sleep due to pain]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context. Note: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings. "Overall" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks. |
| up to Week 15 |
| Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf]) | A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome. | Week 15 |
| Change From Baseline in Pain Interference Index (BPI-sf) | BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. It consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes). The BPI-sf pain interference index was calculated as average of the seven individual pain interference scores. | Week 15 |
| Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores | A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale. | Week 15 |
| Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score. | MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours. | Baseline |
| Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score. | MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours. | Week 15 |
| Percentage of Participants in MOS-SS With Optimal Sleep Status. | MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable. | Week 15 |
| Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%. | Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7*(n-1) to Day 1+7*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain. | Week 15 |
| Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50% | Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7*(n-1) to Day 1+7*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain. | Week 15 |
| Goodyear |
| Arizona |
| 85395 |
| United States |
| Elite Clinical Studies, LLC | Phoenix | Arizona | 85018 | United States |
| HOPE Research Institute | Phoenix | Arizona | 85018 | United States |
| The Pain Center of Arizona | Phoenix | Arizona | 85018 | United States |
| Arizona Research Center | Phoenix | Arizona | 85023 | United States |
| The Pain Center of Arizona | Phoenix | Arizona | 85027 | United States |
| Neuromuscular Research Center | Phoenix | Arizona | 85028 | United States |
| Quality of Life Medical & Research Centers, LLC | Tucson | Arizona | 85712 | United States |
| Advanced Rx Clinical Research | Artesia | California | 90701 | United States |
| Behavioral Research Specialists, LLC | Glendale | California | 91206 | United States |
| NervePro Medical Corp. | Irvine | California | 92618 | United States |
| University of California, Irvine | Irvine | California | 92697 | United States |
| Clinical and Translational Research Institute | La Jolla | California | 92093 | United States |
| Alliance Research Centers | Laguna Hills | California | 92653 | United States |
| South Orange County Surgical Medical Group | Laguna Hills | California | 92653 | United States |
| Center For United Research, Inc. | Lakewood | California | 90805 | United States |
| University of Southern California | Los Angeles | California | 90033 | United States |
| USC I.D.S. Pharmacy | Los Angeles | California | 90089 | United States |
| Samaritan Center for Medical Research | Los Gatos | California | 95032 | United States |
| North County Clinical Research | Oceanside | California | 92056 | United States |
| Allied Clinical Research | Roseville | California | 95661 | United States |
| Northern California Research | Sacramento | California | 95821 | United States |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | United States |
| Elite Clinical Trials, Inc. | Wildomar | California | 92595 | United States |
| Colorado Clinic | Boulder | Colorado | 80301 | United States |
| Mountain View Clinical Research Inc. | Denver | Colorado | 80209 | United States |
| St. Luke's Medical Clinic | Fort Collins | Colorado | 80525 | United States |
| Investigational Drug Services, The George Washington University Medical Center | Washington D.C. | District of Columbia | 20037 | United States |
| The George Washington University Medical Center (Department of Neurology) | Washington D.C. | District of Columbia | 20037 | United States |
| The George Washington University Medical Center | Washington D.C. | District of Columbia | 20037 | United States |
| Orthopedic Research Institute | Boynton Beach | Florida | 33472 | United States |
| Advance Medical Research | Clearwater | Florida | 33756 | United States |
| Innovative Research of West Florida | Clearwater | Florida | 33756 | United States |
| Aga Clinical Trials | Hialeah | Florida | 33012 | United States |
| Health Care Family Rehab & Research Center | Hialeah | Florida | 33012 | United States |
| Research in Miami, Inc. | Hialeah | Florida | 33013 | United States |
| Homestead Medical Research , Inc. | Homestead | Florida | 33030 | United States |
| San Marcus Research Clinic, Inc. | Miami | Florida | 33015 | United States |
| Advanced Pharma CR, LLC | Miami | Florida | 33136 | United States |
| Florida International Research Center | Miami | Florida | 33173 | United States |
| Kendall South Medical Center, Inc. | Miami | Florida | 33185 | United States |
| AMPM Research Clinic | Miami Gardens | Florida | 33169 | United States |
| Compass Research, LLC | Orlando | Florida | 32806 | United States |
| A-One Family Practice | Ormond Beach | Florida | 32174 | United States |
| Aba Family Medicine, LLC | Ormond Beach | Florida | 32174 | United States |
| Ribo Research, LLC dba Peninsula Resarch | Ormond Beach | Florida | 32174 | United States |
| Comprehensive Pain Care of South Florida | Royal Palm Beach | Florida | 33411 | United States |
| Sarasota Pain Medicine Research | Sarasota | Florida | 34238 | United States |
| Meridien Research | Tampa | Florida | 33634 | United States |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30331 | United States |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | United States |
| Georgia Institute for Clinical Research, LLC | Marietta | Georgia | 30060 | United States |
| Advanced Internal Medicine, PC | Stockbridge | Georgia | 30281 | United States |
| Research 1 Clinical Research Network, Inc. (Administrative Office Only) | Stockbridge | Georgia | 30281 | United States |
| Rehabilitation Institute of Chicago | Chicago | Illinois | 60611 | United States |
| Chicago Anesthesia Associates | Chicago | Illinois | 60657 | United States |
| Kansas City Bone & Joint Clinic | Overland Park | Kansas | 66211 | United States |
| Otri-Med Corporation | Edgewood | Kentucky | 41017 | United States |
| Central Kentucky Research Associates, Inc. | Lexington | Kentucky | 40509 | United States |
| Centex Studies, Inc | Lake Charles | Louisiana | 70601 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Michigan Head Pain and Neurological Institute | Ann Arbor | Michigan | 48104 | United States |
| Medex Healthcare Research, Inc. | St Louis | Missouri | 63117 | United States |
| Quality Clinical Research, Inc. | Omaha | Nebraska | 68114 | United States |
| Heartland Clinical Research, Inc. | Omaha | Nebraska | 68134 | United States |
| Advanced Biomedical Research of America | Las Vegas | Nevada | 89123 | United States |
| University of Rochester, Translational Pain Research | Rochester | New York | 14618 | United States |
| PMG Research of Charlotte | Charlotte | North Carolina | 28209 | United States |
| PMG Research of Winston-Salem | Winston-Salem | North Carolina | 27103 | United States |
| Northern Ohio Neurosciences, LLC | Bellevue | Ohio | 44811 | United States |
| Wells Institute for Health Awareness | Kettering | Ohio | 45429 | United States |
| Northwest Ohio Research Center, LLC | Toledo | Ohio | 43623 | United States |
| Robert L Kalb, M.D, Inc | Toledo | Ohio | 43623 | United States |
| Cor Clinical Research, Llc | Oklahoma City | Oklahoma | 73103 | United States |
| Lynn Health Science Institute | Oklahoma City | Oklahoma | 73112 | United States |
| Summit Research Network, Inc. | Portland | Oregon | 97210 | United States |
| Allegheny Pain Management, P.C. | Altoona | Pennsylvania | 16602 | United States |
| CRI Lifetree | Philadelphia | Pennsylvania | 19139 | United States |
| Pharmacorp Clinical Trials, Inc. | Charleston | South Carolina | 29412 | United States |
| TLM Medical Services, LLC | Columbia | South Carolina | 29204 | United States |
| Piedmont Comprehensive Pain Management Group, LLC | Greenville | South Carolina | 29601 | United States |
| Pharmacum Biomedical Research | Greenville | South Carolina | 29605 | United States |
| New Phase Research and Development | Knoxville | Tennessee | 37919 | United States |
| Dallas Pain Consultants | Dallas | Texas | 75203 | United States |
| FutureSearch Trials of Dallas, L. P. | Dallas | Texas | 75231 | United States |
| Abigail R. Neiman, MD, PA | Houston | Texas | 77024 | United States |
| Agadadash Kuliev, MD, PA | Houston | Texas | 77043 | United States |
| Biopharma Informatic Inc. Research Center | Houston | Texas | 77043 | United States |
| Medstar Clinical Research Associates | Houston | Texas | 77083 | United States |
| ClinRx Research, LLC | Richardson | Texas | 75080 | United States |
| DCT - Stone Oak, LLC dba Discovery Clinical Trials | San Antonio | Texas | 78258 | United States |
| Sealy Urgent Care Center and Medical Clinic | Sealy | Texas | 77474 | United States |
| Grayline Clinical Drug Trials | Wichita Falls | Texas | 76309 | United States |
| Lifetree Clinical Research | Salt Lake City | Utah | 84106 | United States |
| J. Lewis Research, Inc./Foothill Family Clinic | Salt Lake City | Utah | 84109 | United States |
| J. Lewish Research, Inc./Foothill Family Clinic South | Salt Lake City | Utah | 84121 | United States |
| Integrated Neurology Services , PLLC | Arlington | Virginia | 22205 | United States |
| IntegraTrials, LLC | Arlington | Virginia | 22205 | United States |
| Washington Center for Pain Management LLC | Bellevue | Washington | 98004 | United States |
| Northwest Clinical Research Center | Bellevue | Washington | 98007 | United States |
| Washington Center for Pain Management LLC | Edmonds | Washington | 98026 | United States |
| Washington Center for Pain Management LLC | Everett | Washington | 98201 | United States |
| Washington Center for Pain Management LLC | Renton | Washington | 98055 | United States |
| Summit Research Network (Seattle) LLC | Seattle | Washington | 98104 | United States |
| MHAT Puls AD | Blagoevgrad | 2700 | Bulgaria |
| MHAT "Avis Medika" | Pleven | 5800 | Bulgaria |
| MHAT "Sv.Pantaleymon" | Pleven | 5800 | Bulgaria |
| DCC Akta Medika Ltd. | Sevlievo | 5400 | Bulgaria |
| UMHAT Aleksandrovska | Sofia | 1431 | Bulgaria |
| DCC "Sveta Anna"EOOD | Sofia | 1709 | Bulgaria |
| Aggarwal and Associates Limited | Brampton | Ontario | L6T 0G1 | Canada |
| NRK Medical Research Clinic (Adminstrative Office Only) | London | Ontario | N6H 4P2 | Canada |
| NRK Medical Research Clinic | London | Ontario | N6H 4P2 | Canada |
| London Road Diagnostic Clinic and Medical Centre | Sarnia | Ontario | N7T 4X3 | Canada |
| General Hospital "dr. Ivo Pedisic" | Sisak | 44000 | Croatia |
| Glostrup Hospital | Glostrup Municipality | 2600 | Denmark |
| Klinische Forschung Hannover-Mitte GmbH | Hanover | Lower Saxony | 30159 | Germany |
| Praxis für Spezielle Schmerztherapie und Palliativmedizin | Böhlen | Saxony | 04564 | Germany |
| medamed GmbH Studienambulanz | Leipzig | Saxony | 04109 | Germany |
| pro scientia med im MARE Klinikum | Kiel-Kronshagen | Schleswig-Holstein | 24119 | Germany |
| Klinische Forschung Berlin-Mitte GmbH | Berlin | 10117 | Germany |
| Synexus Clinical Research GmbH | Berlin | 12627 | Germany |
| Synexus Clinical Research GmbH | Bochum | 44787 | Germany |
| Synexus Clinical Research GmbH | Frankfurt | 60596 | Germany |
| Klinische Forschung Hamburg GmbH | Hamburg | 20253 | Germany |
| Gemeinschaftspraxis für Schmerz- und Psychotherapie | Hamburg | 22767 | Germany |
| Synexus Clinical Research GmbH | Leipzig | 04103 | Germany |
| Klinische Forschung Schwerin GmbH | Schwerin | 19055 | Germany |
| Synexus Magyarorszag Kft. | Budapest | 1036 | Hungary |
| UNO Medical Trials Kft | Budapest | 1135 | Hungary |
| Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz | Miskolc | 3526 | Hungary |
| Niepubliczny Zaklad Opieki Zdrowotnej "Przychodnia Morena" Sp. z.o.o. | Gdansk | 80-286 | Poland |
| "SYNEXUS POLSKA" Sp. z o.o. Oddzial w Gdyni | Gdynia | 81-384 | Poland |
| "Synexus Polska" Sp. z o.o. Oddzial W Katowicach | Katowice | 40-040 | Poland |
| Malopolskie Centrum Medyczne S.C. | Krakow | 30-510 | Poland |
| NZOZ IGNIS dr n. med. Alicja Lobinska | Åšwidnik | 21-040 | Poland |
| "SYNEXUS Polska" Sp. z o.o. ODDZIAL W WARSZAWIE | Warsaw | 01-192 | Poland |
| "SYNEXUS POLSKA" Sp. z o.o. Odzial we Wroclawiu | Wroclaw | 50-088 | Poland |
| Ponce School of Medicine, CAIMED Center | Ponce | 00716 | Puerto Rico |
| Centrul Medical Sana | Bucharest | 011025 | Romania |
| Clubul Sanatatii SRL | Campulung Muscel | 115100 | Romania |
| Spitalul Clinic de Neuropsihiatrie Craiova | Craiova | 200473 | Romania |
| Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea,Sectia Neurologie I | Oradea | 410154 | Romania |
| Spitalul Clinic Judetean de Urgenta Sibiu,Sectia Neurologie | Sibiu | 550166 | Romania |
| Spitalul Clinic Judetean de Urgenta Targu-Mures , Sectia Neurologie II | Târgu Mureş | 540136 | Romania |
| Welkom Clinical Trial Centre | Welkom | Free State | 9460 | South Africa |
| Synexus SA - Stanza Clinical Research Centre | Pretoria | Gauteng | 0122 | South Africa |
| Synexus SA - Watermeyer Clinical Research Centre | Pretoria | Gauteng | 0184 | South Africa |
| Synexus SA - Roodepoort Medicross Clinical Research Centre | Roodeport | Gauteng | 1724 | South Africa |
| Seoul National University Hospital | Seoul | 110-744 | South Korea |
| Ladulaas Kliniken | Borås | 506 30 | Sweden |
| CTC, Gothia Forum, Sahlgrenska Universitetssjukhus | Gothenburg | 413 45 | Sweden |
| Probare | Lund | 222 22 | Sweden |
| Pharmasite | Malmö | 211 52 | Sweden |
| Bragee Medect AB | Stockholm | 115 26 | Sweden |
Participants randomized to receive placebo
| TREATED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Pregabalin | Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase. |
| BG001 | Placebo | Participants randomized to receive placebo |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Age, Customized | Number | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Baseline Mean Pain Score | This is based on the daily pain dairy and is defined as the baseline mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. | Intent to Treat (ITT) population: all randomized participants who took at least one dose of study drug | Posted | Mean | Standard Deviation | units on a scale | Baseline |
|
|
| ||||||||||||||||||||||||||||
| Primary | Change From Baseline to Week 15 in Weekly Mean Pain Score | This is based on the daily pain diary and is defined as the change from baseline to week 15 in mean pain diary score. The Daily Pain Diary consists of an 11-point numeric rating scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Subjects describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Least Squares Mean | Standard Error | units on a scale | up to Week 15 |
|
| |||||||||||||||||||||||||||||
| Secondary | Patient Global Impression of Change (PGIC) at Week 15 | A self administered instrument that measures changes in participants' overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). The PGIC is based on the Clinical Global Impression of Change, which is a validated scale. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Number | Participants | Week 15 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Overall Weekly Mean Sleep Interference Score (SIRS) | This is an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" [unable to sleep due to pain]). Participants describe how pain has interfered with their sleep during the past 24 hours. Please note that the data for Baseline (raw scores) have been included in the below table to read the change from Baseline data in context. Note: Weekly mean SIRS scores were derived from the daily sleep diary and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean SIRS scores were defined as the mean of the 7 daily diary SIRS scores from Day 2+7 (n-1) to Day 1+7*n. For participants with multiple diary scores collected on the same day, the average of all non-missing scores for that day was used in any analyses or data listings. "Overall" is the pooled average sleep interference score for each subject across all post-baseline/randomization weeks. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Mean | Standard Deviation | units on a scale | up to Week 15 |
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Pain Severity Index (Brief Pain Inventory-short Form [BPI-sf]) | A self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. The BPI-sf consists of 5 questions. Four items measure pain on 11-point response scales from 0 (No Pain) to 10 (Pain as bad as you can imagine). In the above scale, score 0 indicates the better outcome whereas score 10 indicates the worse outcome. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Least Squares Mean | Standard Error | units on a scale | Week 15 |
|
| |||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Pain Interference Index (BPI-sf) | BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24 hour period prior to evaluation. It consists of 7 sub-questions that evaluates the level of pain interference with daily functioning on 11-point response scales from 0 (does not interfere) to 10 (completely interferes). The BPI-sf pain interference index was calculated as average of the seven individual pain interference scores. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Least Squares Mean | Standard Error | units on a scale | Week 15 |
|
| |||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Endpoint in Quality of Life Using EuroQol (EQ-5D) Health State Profile Scores | A self-administered questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression. Each dimension is rated on a 3 point response scale and the scores are combined to form a single index value between 0 and 1 with higher scores being more positive (better health status). The EQ-5D was completed by the subject at week-0 and week-15/ET where 30% responder and 50% responder status would be defined for each participants based on the percent change from baseline (week 0/Randomization) to each visit week in mean pain score and participant global impression of change (PGIC). PGIC is a self-administered instrument that measures change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). It is based on the Clinical Global Impression of Change CGIC), which is a validated scale. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Least Squares Mean | Standard Error | Units on a scale | Week 15 |
| ||||||||||||||||||||||||||||||
| Secondary | Baseline Scores in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score. | MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours. | ITT population: all randomized participants who took at least one dose of study drug. | Posted | Median | Full Range | Units on a scale | Baseline |
| ||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in the Medical Outcomes Study Sleep Scale (MOS-SS) - Sub-domain Score. | MOS-SS is a self administered measure consisting of twelve items that assess the key constructs of sleep. Instrument scored results in 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, quantity of sleep, optimal sleep, sleep adequacy, somnolence. Two index measures that assess sleep disturbance was also constructed to provide composite scores. Sleep disturbance, snoring, somnolence, awaken short of breath, and the 9 items sleep problems index all have score ranges from 0 (no sleep problems) to 100 (greater sleep problems), therefore a negative change indicates improvement. Sleep adequacy is scored 0 (least sleep adequacy) to 100 (better sleep adequacy), therefore a positive change indicates improvement. Quantity of sleep is scored 0 (less quantity of sleep) to 24 (greater quantity of sleep), therefore a positive change indicates improvement. Optimal sleep is scored Yes if average hours of sleep is in range of 7-8 hours. | ITT population: all randomized participants who took at least one dose of study drug. | Posted | Least Squares Mean | 95% Confidence Interval | Units on a scale | Week 15 |
| ||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants in MOS-SS With Optimal Sleep Status. | MOS-SS optimal sleep status analyzed on a scale of four parameters: any improvements, no change, any worsening and not applicable. | ITT population: all randomized subjects who took at least one dose of study drug | Posted | Number | Percentage of participants | Week 15 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥30%. | Participants with at least 30% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7*(n-1) to Day 1+7*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Number | Percentage of participants | Week 15 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Percentage of Responders to Treatment With Pregabalin Measured as Reduction in Mean Pain Score of ≥50% | Participants with at least 50% reduction in the mean pain score from baseline to each week. Weekly mean pain NRS scores are derived from the daily pain NRS and calculated as the mean of the available scores in the 7 days. Generally, week 'n' mean pain score is defined as the mean of the 7 daily diary pain ratings from Day 2+7*(n-1) to Day 1+7*n. At least 4 entries within the last 7 days are required to calculate a mean score. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scored indicating increased pain. | ITT population: all randomized participants who took at least one dose of study drug | Posted | Number | Percentage of participants | Week 15 |
|
|
From Day -21 to Day 112 (week 16) i.e. from baseline until 1 day post last taper dose.
The adverse events reporting period was from the signing of the informed consent (at screening) throughout the study including 28 calendar days from the last dose of study medication.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Pregabalin | Participants randomized to receive pregabalin: a 3-week dose optimization phase followed by 150 mg, 300 mg, 450 mg or 600 mg per day dosing 12-week maintenance phase. | 2 | 274 | 75 | 274 | ||
| EG001 | Placebo | Participants randomized to receive placebo | 7 | 265 | 33 | 265 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Concussion | Injury, poisoning and procedural complications | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Post procedural discharge | Injury, poisoning and procedural complications | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Hypoglycaemic seizure | Nervous system disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Major depression | Psychiatric disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA version 18.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA version 18.1 | Non-systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA version 18.1 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer Clinical Trials.gov Call Center | Pfizer, Inc | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| ID | Term |
|---|---|
| D009437 | Neuralgia |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069583 | Pregabalin |
| ID | Term |
|---|---|
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
| 45 - 64 years |
|
| >=65 years |
|
| Male |
|
|
|
|
|
|
|
|
|
|
|
|
Participants randomized to receive placebo
|
|
|
|
|
Participants randomized to receive placebo
|
|
|
|
|
|
|
|
|
|
|